Company Profile
Hybio Pharmaceutical provides the research, development, production, and marketing of peptide and oligonucleotide drugs in China and globally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis Disposable injectable pens.
Its portfolio also includes peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases, digestive system diseases, neoplasms, nervous system diseases, pregnancy, childbirth, and puerperium, musculoskeletal system and connective tissue diseases, infectious and parasitic diseases, circulatory system diseases, blood and hematopoietic organ diseases, and genitourinary system diseases, as well as factors influencing health status, as well as contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates. Additionally, it provides property services. Founded in 1998, Hybio Pharmaceutical is headquartered in Wuhan, China.